Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,773.00+1.32%ETH$2,291.57+1.58%GOLD$3,940.20-0.74%OIL$96.79+0.34%
Smart Investors Daily
SID Premium
ZV

NASDAQ · ZVRA

Zevra Therapeutics, Inc.

Healthcare · Biotechnology

$10.10

Up+$0.16 (+1.58%)

Updated Nov 3, 2026, 9:58 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
472.31M
P/E ratio
173.83
Dividend yield
0.00%
52-week range
$8.01 – $15.04
Volume
638.27K
Avg. volume
1.88M

Price performance · ZVRA

ZVRA price history

1M range · 0 trading sessions · Daily adjusted prices

ZVRA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ZVRA news

The latest Smart Investors Daily articles mentioning ZVRA.

Stock researchCompany · Overview

ZVRA research

Overview

Company profile and research snapshot.

Company profile

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$24.00
Implied upside
—
Analysts
—
ZVRA recent ratings
DateFirmRatingTarget
Aug 20, 2026HC Wainwright & Co.Buy—
Aug 7, 2026GuggenheimBuy—
Aug 6, 2026CitizensMarket Outperform—
Jul 27, 2026GuggenheimBuy—
Jul 27, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the third quarter on Tuesday, November 3, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By